

SEP 25 2001

510(k) SUMMARY

K012074-

By 182

**XBO1-1-824-18/19/20
Biopsy Forceps**

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR, Section 807.92.

A. Submitter's Name, Address, Phone and Fax Number

1. Manufacturer of the subject device

| | |
|--|---|
| Name & Address of Manufacturer; | Olympus Optical Co., Ltd. 2-3-1 Shinjuku Monolis Nishi-shinjuku Shinjuku-ku, Tokyo, 163-0914 Japan |
| Registration No : | 8010047 |
| Address, Phone and Fax Number of R&D Department | 2951 Ishikawa-cho Hachioji-shi, Tokyo 192-8507 Japan |
| Endoscope Division | TEL 81-426-42-5177 FAX 81-426-46-5613 |

2. Name of Contact Person

| | |
|--------------------------|---|
| Name : | Ms. Laura Storms-Tyler Director, Regulatory Affairs Olympus America Inc. Two Corporate Center Drive Melville, NY 11747-3157 |
| Address, Phone and Fax : | TEL (631) 844-5688 FAX (631) 844-5416 |

B. Device Name, Common Name

| | |
|--------------------------|-------------------------------------|
| 1. Device Name : | XBO1-824-18/19/20 Biopsy Forceps |
| 2. Common/Usual Name : | Biopsy Forceps |
| 3. Classification Name : | 21CFR 876.1075 21CFR 876.1500 |

K012074
Pg 2 of 2

C. Predicate Devices:

| Model | Device Description & 510(k)#/ Date Cleared | Manufacturer |
|----------------------------|--|----------------------|
| Multiple Biopsy Device MBx | #K911448 04/16/1991 | Triton Technology |
| FB Series Biopsy Forceps | #K955065 01/24/1996 | Olympus Optical Co., |

D. Description of the Device

This instrument has been designed to be used with an Olympus endoscope to collect tissue within the upper and lower digestive tract and to extract the tissue sample through the biopsy forceps with suction.

The Olympus Biopsy Forceps XBO1-824-18/19/20 are composed with three major components as follows:

1. Biopsy Forceps (XBO1-824-18/19/20)

The mechanism of subject device for collecting biopsied tissue is that biopsied tissue is caught onto Specimen trap by injected water through the biopsy forceps and it is possible to collect 5 samples continually.

2. Suction Tube (XBO1-824-18C)

This device is for connecting the thumb ring valve to the suction source.

3. Specimen Trap (XBO1-824-18D)

The Specimen Trap has a filter for the specimen to be aspirated through the Aspiration Lumen, which can be attached onto the proximal section of the Biopsy Forceps. The Specimen Trap is comprised with five independent filters, which are arrayed serially. After it catches the specimen, the filter that holds the specimen, is extruded from the proximal handle of the Biopsy Forceps, and snapped off into an individual section. To avoid unexpected breakage of the Trap, the Trap Support guides the sections of the Traps. When the section of the Specimen Trap is inserted into the proximal handle, it will make a "click" sound, and the first Trap will be centered at the axis of the Aspiration automatically.

E. Intended Use of the device

This instrument has been designed to be used with an Olympus endoscope to collect tissue within the digestive tract and to extract the tissue sample through the biopsy forceps with suction.

F. Reason for not requiring clinical data

Compared to the predicate devices, "Biopsy Forceps XBO1-824-18/19/20" does not incorporate any significant changes in intended use, methods of operations, materials, or design that could affect the safety and effectiveness.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

SEP 25 2001

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

Ms. Laura Storms-Tyler
Director, Regulatory Affairs
Olympus America, Inc.
Two Corporate Center Drive
MELVILLE NY 11747-3157

Re: K012074
Trade/Device Name: XBO1-824-18/19/20 Biopsy
Forceps
Regulation Number: 21 CFR §876.1500
Regulation Name: Endoscope and accessories
Regulatory Class: II
Product Code: 78 KOG
Regulation Number: 21 CFR §876.1075
Regulation Name: Gastroenterology-urology
biopsy instrument
Regulatory Class: I (exempt)
Product Code: 78 FCT
Dated: June 29, 2001
Received: July 2, 2001

Dear Ms. Storms-Tyler:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (sections 531-542 of the Act); 21 CFR 1000-1050.


This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of this letter:

| | |
|----------------------------------|----------------|
| 8xx.1xxx | (301) 594-4591 |
| 876.2xxx, 3xxx, 4xxx, 5xxx | (301) 594-4616 |
| 884.2xxx, 3xxx, 4xxx, 5xxx, 6xxx | (301) 594-4616 |
| 892.2xxx, 3xxx, 4xxx, 5xxx | (301) 594-4654 |
| Other | (301) 594-4692 |

Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>.

Sincerely yours,



Nancy C. Brogdon
Director, Division of Reproductive,
Abdominal, and Radiological Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure

K012074

510(k) Number (if known):

Device Name: BIOPSY FORCEPS

Indications for Use:


Olympus BIOPSY FORCEPS has been designed to be used with an Olympus endoscope to collect tissue samples within the upper and lower digestive tract and to extract the tissue samples through the biopsy forceps with suction.

(Division Sign-Off)

Division of Reproductive, Abdominal,
and Radiological Devices

510(k) Number

K012074



Concurrence of CDH, Office of Device Evaluation ODE

Prescription Use ☒

OR

Over-The-Counter Use

(Per 21 CFR 876.4400)

(Optional Format 1-2-96)